AIM: To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME). METHODS: A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected with persistent DME. Best corrected visual acuity (BCVA) was assessed through Early Treatment Diabetic Retinopathy Study (ETDRS). Central macular thickness (CMT) was measured by spectral-domain optical coherence tomography. BCVA and CMT examinations were carried out at baseline (T0) and repeated after three days, one month (T1), three months (T3), four months (T4), and six months (T6) post injection. RESULTS: Dexamethasone implant induced an improvement in ETDRS at T1, T3, T4, and T6 post injection. CMT was reduced at T1, T3, and T4, while at T6, CMT values were not statistically different from baseline. No complications were observed during the follow-up. CONCLUSION: Our data suggest that dexamethasone implant is effective in reducing DME symptoms within a six-month frame.

Intravitreal injection of Ozurdex(®) implant in patients with persistent diabetic macular edema, with six-month follow-up / Pacella, F; Ferraresi, Af; Turchetti, P; Lenzi, T; Giustolisi, R; Bottone, A; Fameli, Valeria; Romano, Mr; Pacella, Elena. - In: OPHTHALMOLOGY AND EYE DISEASE. - ISSN 1179-1721. - ELETTRONICO. - 8:(2016), pp. 11-16. [10.4137/OED.S38028]

Intravitreal injection of Ozurdex(®) implant in patients with persistent diabetic macular edema, with six-month follow-up

Pacella F
Primo
;
Ferraresi AF
Secondo
;
Turchetti P;Lenzi T;Giustolisi R;Bottone A;FAMELI, VALERIA;PACELLA, Elena
Ultimo
2016

Abstract

AIM: To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME). METHODS: A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected with persistent DME. Best corrected visual acuity (BCVA) was assessed through Early Treatment Diabetic Retinopathy Study (ETDRS). Central macular thickness (CMT) was measured by spectral-domain optical coherence tomography. BCVA and CMT examinations were carried out at baseline (T0) and repeated after three days, one month (T1), three months (T3), four months (T4), and six months (T6) post injection. RESULTS: Dexamethasone implant induced an improvement in ETDRS at T1, T3, T4, and T6 post injection. CMT was reduced at T1, T3, and T4, while at T6, CMT values were not statistically different from baseline. No complications were observed during the follow-up. CONCLUSION: Our data suggest that dexamethasone implant is effective in reducing DME symptoms within a six-month frame.
2016
dexamethasone; diabetes; intravitreal implant; macular edema
01 Pubblicazione su rivista::01a Articolo in rivista
Intravitreal injection of Ozurdex(®) implant in patients with persistent diabetic macular edema, with six-month follow-up / Pacella, F; Ferraresi, Af; Turchetti, P; Lenzi, T; Giustolisi, R; Bottone, A; Fameli, Valeria; Romano, Mr; Pacella, Elena. - In: OPHTHALMOLOGY AND EYE DISEASE. - ISSN 1179-1721. - ELETTRONICO. - 8:(2016), pp. 11-16. [10.4137/OED.S38028]
File allegati a questo prodotto
File Dimensione Formato  
Pacella_Intravitreal Injection of Ozurdex®_2016.pdf

accesso aperto

Note: https://journals.sagepub.com/doi/10.4137/OED.S38028
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 685.16 kB
Formato Adobe PDF
685.16 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/970504
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 44
social impact